Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (“Ligand”) (NASDAQ: LGND) provides the following summary of the material accounting impact of the Viking Therapeutics, Inc. (“Viking”) initial public offering (“IPO”), which closed on May 4, 2015: Ligand’s statement of operations for the second quarter of 2015 is expected to include approximately $28.2 million of non-operating income as “Gain on deconsolidation” primarily related to the equity milestone received from Viking upon th

Print Friendly, PDF & Email

Share This

Share this post with your friends!